VINC - Vincerx Pharma, Inc. Stock Analysis

Stock Taper

SCREENER COMPARE ANY 2 STOCKS

VINC

VINCERX PHARMA, INC.

OTC

$0.01

▲ UP 3.15% (0.00)

KEY STATISTICS

Market Cap$68.57 K

52w High$1.43

52w Low$0.00

Dividend Yield—

Frequency—

P/E—

Volume8.00K

Shares Out.5.23M

COMPANY

LEADERSHIP

CHIEF EXECUTIVE

Raquel E. Izumi

COMPENSATION 2026

Salary$479,167

Stock Awards$0

Incentive Plan Pay$0

All Other Comp.$13,546

Total$734,953

ABOUT

SECTOR

Healthcare

WENT PUBLIC

May 27, 2020

METHOD OF GOING PUBLIC

SPAC

FULL TIME EMPLOYEES

PRICE TARGET

Target High$4.00

Target Low$2.00

Target Median$3.00

Target Consensus$3.00

UPCOMING EARNINGS

DateAug 31, 2026

DayMonday

Rev. Est.—

AUG

MON

SPLIT RECORD

DATE	TYPE	RATIO
2025-01-28	Reverse	1:20

PRICE

$0.01 ▲ UP 3.15% (+$0.00)

OVERLAYS

About Vincerx Pharma, Inc.

https://vincerx.com ↗

Vincerx Pharma, founded in 2019 in Palo Alto, develops cancer therapies, with lead candidate VIP152 and preclinical drugs VIP217, VIP236, VIP943, and VIP924 targeting various malignancies.

INDUSTRY

Biotechnology

A PRODUCT VINCERX PHARMA, INC. IS KNOWN FOR

VIP943

VIP943 is an investigational ADC targeting CD123 on cancer cells, in Phase 1 trials for hematologic malignancies like AML, and is a key asset in Vincerx's pipeline and VersAfin platform.